| Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy S Kato, KH Kim, HJ Lim, A Boichard, M Nikanjam, E Weihe, DJ Kuo, ... Nature communications 11 (1), 4965, 2020 | 250 | 2020 |
| SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy K Mardinian, JJ Adashek, GP Botta, S Kato, R Kurzrock Molecular cancer therapeutics 20 (12), 2341-2351, 2021 | 116 | 2021 |
| Hyperprogression and immunotherapy: fact, fiction, or alternative fact? JJ Adashek, IM Subbiah, I Matos, E Garralda, AK Menta, DM Ganeshan, ... Trends in cancer 6 (3), 181-191, 2020 | 116 | 2020 |
| Phase I trials as valid therapeutic options for patients with cancer JJ Adashek, PM LoRusso, DS Hong, R Kurzrock Nature reviews Clinical oncology 16 (12), 773-778, 2019 | 111 | 2019 |
| From tissue-agnostic to N-of-one therapies:(R) evolution of the precision paradigm JJ Adashek, V Subbiah, R Kurzrock Trends in cancer 7 (1), 15-28, 2021 | 95 | 2021 |
| Caring for the caregiver: a systematic review characterising the experience of caregivers of older adults with advanced cancers JJ Adashek, IM Subbiah ESMO open 5 (5), e000862, 2020 | 88 | 2020 |
| Responses to alectinib in ALK-rearranged papillary renal cell carcinoma SK Pal, P Bergerot, N Dizman, C Bergerot, J Adashek, R Madison, ... Eur Urol 74 (1), 124-128, 2018 | 83 | 2018 |
| Hyperprogression and immune checkpoint inhibitors: hype or progress? JJ Adashek, S Kato, R Ferrara, G Lo Russo, R Kurzrock The oncologist 25 (2), 94-98, 2020 | 73 | 2020 |
| Signed in blood: circulating tumor DNA in cancer diagnosis, treatment and screening JJ Adashek, F Janku, R Kurzrock Cancers 13 (14), 3600, 2021 | 66 | 2021 |
| Understanding genomics and the immune environment of penile cancer to improve therapy AM Aydin, J Chahoud, JJ Adashek, M Azizi, A Magliocco, JS Ross, ... Nature Reviews Urology 17 (10), 555-570, 2020 | 57 | 2020 |
| A phase 1 trial of SGN‐CD70A in patients with CD70‐positive, metastatic renal cell carcinoma SK Pal, A Forero‐Torres, JA Thompson, JC Morris, S Chhabra, ... Cancer 125 (7), 1124-1132, 2019 | 57 | 2019 |
| Agnostic approvals in oncology: getting the right drug to the right patient with the right genomics V Tateo, PV Marchese, V Mollica, F Massari, R Kurzrock, JJ Adashek Pharmaceuticals 16 (4), 614, 2023 | 54 | 2023 |
| Clinical development of PARP inhibitors in treating metastatic castration-resistant prostate cancer JJ Adashek, RK Jain, J Zhang Cells 8 (8), 860, 2019 | 47 | 2019 |
| Integrating somatic and germline next-generation sequencing into routine clinical oncology practice JK Hicks, R Howard, P Reisman, JJ Adashek, KK Fields, JE Gray, ... JCO precision oncology 5, 884-895, 2021 | 46 | 2021 |
| Tissue-agnostic activity of BRAF plus MEK inhibitor in BRAF V600–mutant tumors JJ Adashek, AK Menta, NK Reddy, AP Desai, J Roszik, V Subbiah Molecular cancer therapeutics 21 (6), 871-878, 2022 | 45 | 2022 |
| The paradox of cancer genes in non-malignant conditions: implications for precision medicine JJ Adashek, S Kato, SM Lippman, R Kurzrock Genome medicine 12, 1-19, 2020 | 39 | 2020 |
| Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers JJ Adashek, AP Desai, AY Andreev-Drakhlin, J Roszik, GJ Cote, ... Molecular cancer therapeutics 20 (10), 1769-1776, 2021 | 37 | 2021 |
| Concomitant MEK and cyclin gene alterations: implications for response to targeted therapeutics S Kato, JJ Adashek, J Shaya, R Okamura, RE Jimenez, S Lee, JK Sicklick, ... Clinical Cancer Research 27 (10), 2792-2797, 2021 | 36 | 2021 |
| Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values JJ Adashek, G Genovese, NM Tannir, P Msaouel Cancer treatment and research communications 23, 100166, 2020 | 35 | 2020 |
| Examining public communication about kidney cancer on Twitter MS Sedrak, MM Salgia, C Decat Bergerot, K Ashing-Giwa, BN Cotta, ... JCO Clinical Cancer Informatics 3, 1-6, 2019 | 32 | 2019 |